SYNERCAN

Oncology biotech

Known drugs. New combinations. More effective against cancer.

We bring together repurposed drugs and lipid nanoemulsions to address unmet clinical needs as efficiently as possible.

Find out how
01 / 03

About us

Biotechnology for needs oncology has yet to solve

SYNERCAN develops cancer treatments that combine repurposed drugs with nanoemulsions. We start from medicines with proven safety in humans and look for combinations that act in synergy, to reach effective therapies faster and with less risk.

Our most advanced program targets osteosarcoma, one of the most common paediatric cancers and among the most resistant to chemotherapy.

Researcher working in a cell culture hood
15+ years of research into combination cancer therapies

Repurposed drugs

New uses for approved medicines: lower cost, less time and a known safety profile.

Synergy

Combinations that boost chemotherapy and allow a lower effective dose and less toxicity.

Nanoemulsions

Biocompatible carriers that help the treatment reach its target more effectively.

Lead program · Osteosarcoma

Promising results in preclinical models

We combine a chemotherapy agent with a molecule that enhances its action: they work in synergy and significantly reduce the effective chemotherapy dose and its toxicity.

Explore the technology
Lower doseof chemotherapy for the same effect
Less toxicityprotection against chemotherapy side effects
Smaller tumoursgreater reduction in tumour volume
Almost no metastasesin the lungs in animal models

Partners and supporters

iUIBS · ULPGC CHUIMI DISA Foundation Activa Startups